Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
DOCK1 Regulates Growth and Motility through the RRP1B-Claudin-1 Pathway in Claudin-Low Breast Cancer Cells.
|
31717460 |
2019 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ADAM15 mediates upregulation of Claudin-1 expression in breast cancer cells.
|
31467400 |
2019 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
A high expression of claudin-1 was more frequently observed in the triple-negative BC cohort than in the cohort with positive ER, PR and/or HER2 before (P=0.04) and after chemotherapy (P=0.02).
|
31572543 |
2019 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Impairment of the Gnα11-controlled expression of claudin-1 and MMP-9 and collective migration of human breast cancer MCF-7 cells by DHEAS.
|
29684479 |
2018 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The underlying mechanism is largely unknown, and no obvious mutations in the claudin 1 gene (CLDN1) have been identified to date in breast cancer.
|
27649506 |
2016 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, exogenous IL-18 enhanced breast cancer cell migration and suppressed the expression of the tight junction proteins claudin-1, claudin-3, claudin-4, and claudin-12 in MCF-7 cells.
|
25727011 |
2015 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data demonstrated that lentiviral vector mediated CLDN1 RNA interference has great potential in breast cancer gene therapy by inhibiting EMT and controlling tumor cell growth.
|
26067567 |
2015 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The absence of CLDN1 expression is strongly suggested to be an independent adverse prognostic factor in this heterogeneous subtype of breast cancer.
|
25393310 |
2014 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Collectively, our data suggest that overexpression of DEC1 may promote the invasiveness of breast cancer through downregulation of claudin-1.
|
23426649 |
2013 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we report on the elevated expression of claudin-1 in human breast cancer MCF-7 cells under tumor necrosis factor (TNF)-α treatment.
|
22941467 |
2012 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The inhibition of claudin-1 was also seen in breast cancer T-47D cells.
|
18204077 |
2008 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results indicated that CLDN1 expression correlated with the recurrence status and malignant potential of breast cancer.
|
17611630 |
2007 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
E-box elements in the Claudin-1 promoter were found to play a critical negative regulatory role in breast cancer cell lines that expressed low levels of Claudin-1 transcript.
|
16232121 |
2006 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The significant loss of CLDN1 protein in breast cancer cells suggests that CLDN1 may play a role in invasion and metastasis.
|
15743508 |
2005 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Retroviral-induced CLDN1 reexpression in breast cancer cells results in plasma membrane homing of the protein and reconstitution of paracellular flux inhibition, which is not dependent on the presence of occludin protein.
|
14648703 |
2004 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We have previously identified the human homologue of the murine Cldn1, CLDN1 (SEMP1) that is expressed in normal, mammary gland-derived epithelial cells but is absent in most human breast cancer cell lines.
|
11920682 |
2002 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Likewise, in the breast cancer cell lines, no genetic alterations in the promoter or coding sequences have been identified that would explain the loss of CLDN1 expression.
|
11071387 |
2000 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
SEMP1 mRNA is expressed in human tissues, including adult and fetal liver, pancreas, placenta, adrenals, prostate and ovary but at low or undetectable levels in a number of human breast cancer cell lines.
|
9931503 |
1999 |